Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.46 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9328434 | 0.91 | ACACB (0.54) | FFAR1FFAR4ACACB | |
| SCHEMBL8141107 | 0.91 | ACACB (0.54) | FFAR1FFAR4ACACB | |
| SCHEMBL28256625 | 0.91 | FFAR1 (0.50) | FFAR1FFAR4APPACACBMAPT | |
| SCHEMBL28255909 | 0.90 | CYP1A1 (0.53) | FFAR1FFAR4ACACBMAPTCHRM2 | |
| SCHEMBL9511319 | 0.89 | ACACB (0.53) | FFAR1FFAR4ACACB | |
| SCHEMBL1495032 | 0.88 | FFAR1 (0.61) | FFAR1FFAR4APPCHRM2S1PR1 | |
| SCHEMBL28255391 | 0.86 | FFAR1 (0.48) | FFAR1FFAR4ASIC3 | |
| SCHEMBL6046904 | 0.86 | FFAR1 (0.59) | FFAR1FFAR4APPCHRM2 | |
| SCHEMBL30785014 | 0.86 | FFAR1 (0.59) | FFAR1FFAR4APPCHRM2 | |
| SCHEMBL28839052 | 0.84 | CYP2A6 (0.52) | FFAR1FFAR4ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109422631-B | Synthetic method of indanone compound | 浙江工业大学 | 2021-10-15 | — | — | CN | disclosed |
| CN-109422634-B | Synthetic method of 3-carbonyl indanone compound | 浙江工业大学 | 2021-06-04 | — | — | CN | disclosed |
| CN-108822869-A | A kind of liquid-crystal compounds containing chlorine and combinations thereof and high frequency assembly comprising it | 西安近代化学研究所 | 2018-11-16 | — | — | CN | disclosed |
| CN-108753312-A | A kind of liquid-crystal compounds, preparation method and the composition containing this compound and the high frequency assembly comprising this liquid crystal media | 西安近代化学研究所 | 2018-11-06 | — | — | CN | disclosed |
| US-7728014-B2 | Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity | ALLERGAN, INC. | 2010-06-01 | — | — | US | disclosed |
| EP-2066633-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2064183-A2 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY | Allergan, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008030843-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030838-A2 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080064872-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064872-A1 | HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST BIOLOGICAL ACTIVITY | S1PR4, S1PR3, S1PR1 | FFAR1 23/4885FFAR4 13/4885APP 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.